Drug-therapy combo cuts breast cancer recurrence risk by 25%, Eli Lilly announces
Eli Lilly and Company on Sunday announced positive results in the fight against breast cancer. A drug called Verzenio, also known as abemaciclib, in combination with adjuvant endocrine therapy, was said to “significantly” reduce the risk of breast cancer recurrence by 25% for those with a common subtype of breast cancer. The combo treatment also lowered the risk… Read More »